Tag: antibody-drug conjugates
-
Enhertu’s Phase 3 Win: AI Accelerates Lung Cancer Treatment
Enhertu’s Phase 3 trial success in treating lung cancer highlights the critical role AI played in optimizing the drug’s development. This marks a significant step in personalized medicine, offering new hope for targeted cancer treatments. Read more
-
AI-Driven Precision Oncology: Enhancing Cancer Therapy Development
Ardigen and VERAXA Biotech are collaborating to enhance precision oncology through AI-driven drug discovery, optimizing cancer target selection for T cell engagers and antibody-drug conjugates. This partnership aims to minimize toxicities and improve success rates in cancer therapies. Read more
